Oral Cancer Research Team, Cancer Research Initiatives Foundation (CARIF), 2nd Floor Outpatient Centre, Subang Jaya Medical Centre, 47500 Subang Jaya, Selangor, Malaysia.
Oral Oncol. 2009 Jun;45(6):496-500. doi: 10.1016/j.oraloncology.2008.06.003. Epub 2008 Sep 18.
The MDM2 SNP309 has been associated with increased expression of the protein which could suppress p53 function, and has been shown to modulate risk to cancer. We have previously shown that overexpression of MDM2 is a common event in oral cancers. In the present study, we determined the association between the MDM2 SNP309 polymorphism and oral cancer in 207 oral cancer patients and 116 normal subjects. We genotyped the MDM2 SNP309 by PCR-RFLP. Logistic regression was adapted to calculate odds ratios for MDM2 SNP309 polymorphism from univariate and multivariable adjusted models. Our results suggest that MDM2 SNP309 does not confer increased risk to oral cancer (OR=1.55, 95% CI=0.77-3.11). However, the GG/TG genotype was associated with later disease onset in women above 55 years of age. Collectively, our data suggests that MDM2 SNP309 may modulate the risk to oral cancer and is a modifier of the age at oral cancer onset in women above the age of 55 years.
MDM2 SNP309 与蛋白质表达增加有关，这可能抑制 p53 功能，并且已被证明可以调节癌症风险。我们之前已经表明，MDM2 的过表达是口腔癌中的常见事件。在本研究中，我们在 207 名口腔癌患者和 116 名正常对照中确定了 MDM2 SNP309 多态性与口腔癌之间的关联。我们通过 PCR-RFLP 对 MDM2 SNP309 进行了基因分型。采用逻辑回归从单变量和多变量调整模型计算 MDM2 SNP309 多态性的优势比。我们的结果表明，MDM2 SNP309 不会增加口腔癌的风险（OR=1.55，95%CI=0.77-3.11）。然而，GG/TG 基因型与 55 岁以上女性的疾病发病较晚有关。总的来说，我们的数据表明，MDM2 SNP309 可能调节口腔癌的风险，并且是 55 岁以上女性口腔癌发病年龄的修饰因子。
